These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 27865826

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists.
    De Crem N, Peerlinck K, Vanassche T, Vanheule K, Debaveye B, Middeldorp S, Verhamme P, Peetermans M.
    Thromb Res; 2015 Oct; 136(4):749-53. PubMed ID: 26272306
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G, Blotière PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, Zureik M.
    Circulation; 2015 Sep 29; 132(13):1252-60. PubMed ID: 26199338
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.
    Beyer-Westendorf J, Michalski F, Tittl L, Hauswald-Dörschel S, Marten S.
    Lancet Haematol; 2016 Oct 29; 3(10):e480-e488. PubMed ID: 27692306
    [Abstract] [Full Text] [Related]

  • 7. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
    Nairooz R, Sardar P, Pino M, Aronow WS, Sewani A, Mukherjee D, Paydak H, Maskoun W.
    Int J Cardiol; 2015 Oct 29; 187():345-53. PubMed ID: 25839640
    [Abstract] [Full Text] [Related]

  • 8. Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study.
    Malec K, Broniatowska E, Undas A.
    Lupus; 2020 Jan 29; 29(1):37-44. PubMed ID: 31757182
    [Abstract] [Full Text] [Related]

  • 9. Management of heavy menstrual bleeding during direct oral anticoagulant therapy for recurrent venous thromboembolism: a case report.
    Giustozzi M, Vedovati MC, Agnelli G.
    Blood Coagul Fibrinolysis; 2018 Jun 29; 29(4):391-394. PubMed ID: 29346128
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis.
    Bleker SM, Brekelmans MPA, Eerenberg ES, Cohen AT, Middeldorp S, Raskob G, Büller HR.
    Thromb Haemost; 2017 Oct 05; 117(10):1944-1951. PubMed ID: 28816341
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials.
    Wang W, Su Y, Wu C, Sun Y, Dai N, Chen W, Zhang J, Xu Y, Brindis RG, Xu D, Li J.
    BMC Cardiovasc Disord; 2020 Feb 03; 20(1):53. PubMed ID: 32013892
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
    Brekelmans MP, Bleker SM, Bauersachs R, Boda Z, Büller HR, Choi Y, Gallus A, Grosso MA, Middeldorp S, Oh D, Raskob G, Schwocho L, Cohen AT.
    Thromb Haemost; 2016 Jul 04; 116(1):155-61. PubMed ID: 27010092
    [Abstract] [Full Text] [Related]

  • 19. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
    Di Nisio M, Vedovati MC, Riera-Mestre A, Prins MH, Mueller K, Cohen AT, Wells PS, Beyer-Westendorf J, Prandoni P, Bounameaux H, Kubitza D, Schneider J, Pisters R, Fedacko J, Fontes-Carvalho R, Lensing AW.
    Thromb Haemost; 2016 Sep 27; 116(4):739-46. PubMed ID: 27535349
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.